| 摘要: |
| 目的探讨锁骨上淋巴结（SCLN）转移对接受根治性放化疗的N3-ⅢB期非小细胞肺癌（NSCLC）患者的预后意义。方法回顾性分析245例接受根治性放化疗的N3-ⅢB期NSCLC患者，根据有无SCLN转移分为两组，即SCLN+117例，SCLN-128例。应用Kaplan-Meier法绘制生存曲线，比较总生存（OS）和无进展生存（PFS）；应用Cox比例风险回归模型评估影响生存的独立预后因素。结果所有患者总生存（OS）时间为19（10，31）个月，无进展生存（PFS）时间为10（7，16）个月。SCLN+与SCLN-组患者OS、PFS比较差异无统计学意义（P＞0.05）；病理诊断与临床诊断为SCLN+患者进行比较，OS差异无统计学意义（P＞0.05）。经影响生存的独立预后因素分析，SCLN+不是影响OS、PFS的独立预后因素（均P＞0.05）；原发肿瘤部位、放化疗方式是影响OS的独立预后因素（均P＜0.05）；年龄、原发肿瘤部位、放化疗方式是影响PFS的独立预后因素（均P＜0.05）。SCLN+与SCLN-患者远处转移（DM）率比较，差异无统计学意义（P＞0.05）。结论与SCLN-比较，SCLN+对N3-ⅢB期NSCLC患者接受根治性放化疗的效果影响不大。 |
| 关键词: 锁骨上淋巴结 非小细胞肺癌 根治性放化疗 预后 |
| DOI：10.12056/j.issn.1006-2785.2017.40.8.2017-2927 |
| 分类号: |
| 基金项目:浙江省自然科学基金项目（LQ16H160002） |
|
| Supraclavicular lymph node metastasis is not correlated with the prognosis of N3-stage ⅢB non-small cell lung cancer patients with chemoradiotherapy |
|
|
|
Ningbo Medical Treatment Center Lihuili Hospital
|
| Abstract: |
| Objective To investigate the prognostic significance of supraclavicular lymph node (SCLN) in patients with N3-ⅢB non-small cell lung cancer (NSCLC) treated with chemoradiotherapy. Methods Two hundred and forty-five patients with N3- Ⅲ B NSCLC who were treated with radical chemoradiotherapy were enrolled, including 117 cases with positive
supraclavicular lymph node (SCLN+ group) and 128 cases of negative SCLN (SCLN- group). The overall survival (OS) and progressive free survival(PFS) were analyzed with Kaplan-Meier method. Cox regression for multivariate analysis were performed to determine the effect of several potential confounding variables. Results The median OS and PFS were 19(10, 31) months and
10 (7, 16) months in these patients. There were no significant difference in OS and PFS between SCLN+ and SCLN- groups (P ＞
0.05). The OS was not statistically different between the pathologically and clinically SCLN+ subgroups (P ＞0.05). Multivariate analysis showed that SCLN metastasis was not a significant factor for OS and PFS (all P ＞0.05). Primary tumor location and concurrent chemoradiotherapy were the independent prognosis factors for OS (all P＜0.05). Age less than 60, primary tumor location and concurrent chemoradiotherapy were associated with a favorable PFS (all P ＜0.05). The difference of distant metastasis rate between SCLN+ and SCLN- groups was not significant(P＞0.05). Conclusion When treated with chemora- diotherapy, the outcomes for patients appear to be not correlated with SCLN metastasis in patients with N3-ⅢB NSCLC. |
| Key words: Supraclavicular lymph node Non-small cell lung cancer Chemoradiotherapy Prognosis |
